At Acadia, our pipeline is focused on advancing therapies for underserved neurological and rare disease communities where unmet need remains high. We apply scientific rigor, patient insight, and experience from prior programs to guide development decisions, strengthen global pathways, and invest with long-term discipline across programs at multiple stages of development. Clinical research is complex and outcomes are not guaranteed, but we remain committed to advancing care in areas where progress can make a meaningful difference.
The safety and efficacy of investigational agents and/or investigational uses of approved products listed below have not been established or approved by the FDA. Pipeline information is updated quarterly.
Please read the full Prescribing Information, including Boxed WARNING.
ACP-204 is a novel, highly selective 5HT2A receptor inverse agonist being developed to treat psychosis associated with Alzheimer’s disease.
Acadia recently initiated a Phase 2 study of ACP-204 (also initiated in Lewy Body Dementia Psychosis), and the company expects a major readout for ACP-204 in Alzheimer’s disease psychosis in mid-2026.
ACP-204 is a novel, highly selective 5HT2A receptor inverse agonist being developed to treat psychosis associated with Lewy body dementia (including Parkinson’s disease dementia and Dementia with Lewy Bodies).
Acadia recently initiated a Phase 2 study in LBDP. The program is also positioned for a major readout in related Alzheimer’s disease psychosis studies, with a key ACP-204 readout expected in mid-2026.
ACP-211 is an orally administered, selectively deuterated form of R-norketamine being developed for major depressive disorder.
ACP‑711 is a selective GABAA α3 modulator being developed for essential tremor. Acadia entered into an exclusive worldwide license agreement with Saniona for development and commercialization of ACP-711.
ACP-271 is a GPR88 agonist in development for neuromotor and rare neurodegenerative indications.
ACP‑2591 is a cGP analog licensed from Neuren being developed for Rett syndrome.
ACP‑271 is a GPR88 agonist in development for neuromotor and rare neurodegenerative indications.
Acadia and Stoke Therapeutics have a collaboration to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system (CNS).
